Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
Iterum Therapeutics (Nasdaq: ITRM), a developer of next-generation oral and IV antibiotics targeting multi-drug resistant pathogens, has scheduled its fourth quarter and full year 2024 financial results release for February 7, 2025, before U.S. markets open. The company will host a conference call at 8:30 a.m. ET on the same day, where management will discuss financial results and provide a business update. Investors can access the call via phone (833-470-1428 domestic, 404-975-4839 international) using Access Code 719739, with pre-registration available. An audio webcast will be accessible in the Investors section of the company's website after the call.
Iterum Therapeutics (Nasdaq: ITRM), un sviluppatore di antibiotici orali e IV di nuova generazione che mirano a patogeni multiresistenti, ha programmato il rilascio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 7 febbraio 2025, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà una conferenza telefonica alle 8:30 ET lo stesso giorno, durante la quale la direzione discuterà dei risultati finanziari e fornirà un aggiornamento sull'attività. Gli investitori possono accedere alla chiamata tramite telefono (833-470-1428 nazionale, 404-975-4839 internazionale) utilizzando il Codice di Accesso 719739, con registrazione anticipata disponibile. Una webinaria audio sarà accessibile nella sezione Investitori del sito web dell'azienda dopo la chiamata.
Iterum Therapeutics (Nasdaq: ITRM), un desarrollador de antibióticos orales e IV de siguiente generación dirigidos a patógenos multirresistentes, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 7 de febrero de 2025, antes de la apertura de los mercados en EE. UU. La empresa realizará una conferencia telefónica a las 8:30 a.m. ET el mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización comercial. Los inversores pueden acceder a la llamada por teléfono (833-470-1428 nacional, 404-975-4839 internacional) utilizando el Código de Acceso 719739, con preinscripción disponible. Una transmisión de audio estará accesible en la sección de Inversores del sitio web de la empresa después de la llamada.
Iterum Therapeutics (Nasdaq: ITRM)는 다제내성 병원균을 겨냥한 차세대 경구 및 IV 항생제 개발업체로서, 2024년 4분기 및 연례 재무 결과 발표를 2025년 2월 7일 미국 시장 개장 전에 예정하고 있습니다. 회사는 같은 날 오전 8시 30분 ET에 전화 회의를 개최하며, 경영진이 재무 결과에 대해 논의하고 비즈니스 업데이트를 제공할 것입니다. 투자자들은 전화(국내 833-470-1428, 국제 404-975-4839)를 통해 719739 접근 코드를 사용하여 통화에 접속할 수 있으며, 사전 등록이 가능합니다. 회의 후 회사 웹사이트의 투자자 섹션에서 오디오 웹캐스트를 이용할 수 있습니다.
Iterum Therapeutics (Nasdaq: ITRM), un développeur d'antibiotiques oraux et IV de nouvelle génération visant des pathogènes multirésistants, a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 7 février 2025, avant l'ouverture des marchés aux États-Unis. L'entreprise organisera une conférence téléphonique à 8h30 (ET) le même jour, au cours de laquelle la direction discutera des résultats financiers et fournira une mise à jour sur les affaires. Les investisseurs peuvent accéder à l'appel par téléphone (833-470-1428 national, 404-975-4839 international) en utilisant le code d'accès 719739, avec la possibilité de préinscription. Un webinaire audio sera accessible dans la section Investisseurs du site web de l'entreprise après l'appel.
Iterum Therapeutics (Nasdaq: ITRM), ein Entwickler von Oral- und IV-Antibiotika der nächsten Generation, die gegen multiresistente Krankheitserreger gerichtet sind, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 7. Februar 2025, vor der Eröffnung der US-Märkte, angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, in der das Management die Finanzergebnisse bespricht und ein Update zum Geschäft gibt. Investoren können der Konferenz telefonisch (833-470-1428 national, 404-975-4839 international) mit dem Zugangscode 719739 beitreten, eine vorherige Registrierung ist möglich. Ein Audio-Webcast wird nach dem Anruf im Investorenbereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2024 financial results before the open of the U.S. financial markets on Friday, February 7, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 719739. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/118185211. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) release its Q4 and full year 2024 earnings?
What time is ITRM's Q4 2024 earnings conference call?
How can investors access ITRM's Q4 2024 earnings call?
Where can I find ITRM's Q4 2024 earnings webcast replay?
